Elevation Point Wealth Partners Boosts Amgen Holdings

Institutional investor increases stake in biotech giant by over 600%

Mar. 16, 2026 at 9:19am

Got story updates? Submit your updates here. ›

Elevation Point Wealth Partners LLC, an institutional investor, significantly increased its position in Amgen Inc. (NASDAQ:AMGN) during the third quarter, purchasing an additional 5,370 shares to bring its total holdings to 6,227 shares, valued at $1.76 million. This represents a 626.6% increase in the firm's Amgen position compared to the prior quarter.

Why it matters

Amgen is one of the world's largest independent biotechnology companies, with a focus on developing innovative human therapeutics to address serious illnesses. The company's stock has seen strong performance in recent years, and this sizable increase in holdings by Elevation Point Wealth Partners suggests the firm sees further upside potential in Amgen's shares.

The details

According to a 13F filing with the Securities and Exchange Commission, Elevation Point Wealth Partners LLC purchased 5,370 additional shares of Amgen during the third quarter, bringing its total position to 6,227 shares. This represents a significant 626.6% increase in the firm's Amgen holdings compared to the prior quarter.

  • Elevation Point Wealth Partners LLC increased its Amgen position during the third quarter of the year.

The players

Elevation Point Wealth Partners LLC

An institutional investment firm that manages assets on behalf of clients.

Amgen Inc.

A global biotechnology company that focuses on discovering, developing, manufacturing, and delivering human therapeutics to address serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

Elevation Point Wealth Partners' significant increase in its Amgen holdings suggests the firm sees further upside potential in the biotech company's stock. As one of the world's largest independent biotechnology companies, Amgen's performance is closely watched by investors and analysts alike.